Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Tandem Diabetes Care, Inc. reported revenue of $1.01B, up 7.9% year over year. Operating margin was -18.5% and net margin -20.2%, on a free-cash-flow margin of -2.9% with capital expenditure at 2.0% of revenue. Every figure is computed directly from TNDM's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $1.01B | -18.5% | -20.2% |
| FY2024 | $940M | -10.5% | -10.2% |
| FY2023 | $748M | -31.2% | -29.8% |
| FY2022 | $801M | -11.6% | -11.8% |
| FY2021 | $703M | 3.2% | 2.2% |
How does TNDM compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.